He was born on January 14, 1953 in Kahramanmaraş. He graduated from Kahramanmaraş High School in 1970 and Ankara University Faculty of Medicine in 1976 with first degree. He became Internal Medicine Specialist at the same faculty in 1981. In the same year, he worked on genetic manipulations at the University of Louis Pasteur in Strasbourg. He became Associate Professor in 1987, Medical Oncology Specialist at Istanbul University Oncology Institute in 1991 and Professor in 1995. He is a member of ASCO and certified ESMO. In March 2017, he left the Istanbul University Oncology Institute, where he...
He was born on January 14, 1953 in Kahramanmaraş. He graduated from Kahramanmaraş High School in 1970 and Ankara University Faculty of Medicine in 1976 with first degree. He became Internal Medicine Specialist at the same faculty in 1981. In the same year, he worked on genetic manipulations at the University of Louis Pasteur in Strasbourg. He became Associate Professor in 1987, Medical Oncology Specialist at Istanbul University Oncology Institute in 1991 and Professor in 1995. He is a member of ASCO and certified ESMO. In March 2017, he left the Istanbul University Oncology Institute, where he worked for 29 years, and started to work in Istinye University Faculty of Medicine Bahçeşehir Liv Hospital. He served as a member of the Board of Medical Oncology Association and Oncology Group Association - Turkish Oncology Group. He is married with one child and has 121 publications in Turkish, English and French in various medical books and journals, and 109 papers presented at national and international congresses. 41 of his publications have been published in PubMed indexed journals. His publications have been cited in 3492 by February 2020 and his H-index: 16, i10-index: 22 (Source: www.googlescholar.com). His principal clinical research interests have been in gastrointestinal cancers. He has participated to some international studies such as PETACC-1, CPT-CMA 202, Aventis V-306, V-307, CRYSTAL, RADIANT-2, CORRECT, RILOMET, REGARD and MODUL. His another area of interest is theoretical biology, especially intercellular communication. He is in the editorial board of the World Journal of Gastrointestinal Oncology (2018), Turkish Journal of Cancer (2003) and Acta Oncologica (Turkish Edition) (2004). Prof. N. Faruk Aykan speaks English and French.
Articles
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
, 2022
Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?
, 2014
Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients
, 2019
Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.
, 2001
A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma.
, 1998
Prognostic significance of the metastatic lymph node ratio for survival in colon cancer
, 2011
A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma
, 2011
Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients
, 2014
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study
, 2016
Clinical significance of serum interleukin-17 levels in colorectal cancer patients
, 2016
Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: a family report
, 2017
Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers
, 2018
Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study
, 2018
Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study
, 2018
CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA
, 2017
Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer
, 2017
CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A POTENTIALBIOMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA
, 2017
Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers.
, 2017
Effect of increased body mass index BMI on time to tumour progression TTP in unresectable metastatic colorectal cancer mCRC patients treated with bevacizumab based therapy
, 2013
Serum neural precursor cell expressed developmentally down regulated 9 NEDD9 level may have a prognostic role in patients with gastric cancer
, 2015
Red meat and colorectal cancer
, 2016
Red meat subtypes and colorectal cancer risk
, 2015
Detection of human papillomavirus DNA by polymerase chain reaction and southern blot hybridization in colorectal cancer patients
, 2009
The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival
, 2000
The role of UFT in advanced gastric cancer
, 2008
Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer
, 2004
Prognostic Factors in Pancreatic Carcinoma Serum LDH Levels Predict Survival in Metastatic Disease
, 2001
Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection can we avoid radiotherapy in a subgroup of patients
, 2013
Penile metastasis of cutaneous malignant melanoma a true hematogenous spread Case report and review of the literature
, 2006
Clinical significance of serum claudin 1 and claudin 7 levels in patients with colorectal cancer
, 2015
Evaluation of Serum Interleukin 17 IL 17 Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma
, 2015
Serum nectin 2 levels are diagnostic and prognostic in patients with colorectal carcinoma
, 2015
Epidemiology of colorectal cancer in Turkey A cross sectional disease registry study A Turkish Oncology Group trial
, 2015
Books
Body-mass Index and Health – Intechopen
Current Frontiers and Perspectives in Cell Biology – InTech
İleri evre mide kanserinde tedavi yaklaşımları – Ortadoğu reklam tanıtım yayıncılık A.Ş
İleri evre mide kanserinde tedavi yaklaşımları – Ortadoğu reklam tanıtım yayıncılık A.Ş
